Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study

苯溴马隆 医学 痛风 安慰剂 内科学 不利影响 尿酸 耐受性 临床终点 随机对照试验 胃肠病学 高尿酸血症 替代医学 病理
作者
Yanwei Lin,Xiaoxiang Chen,Huihua Ding,Ping Ye,Jieruo Gu,Xiaoxia Wang,Zhenyu Jiang,Detian Li,Zhongming Wang,Wubin Long,Zhijun Li,Gengru Jiang,Xiaomei Li,Liqi Bi,Lindi Jiang,Jian Hui Wu,Lian Guo,Xiaoyan Cai,Xin Lu,Qinkai Chen
出处
期刊:Rheumatology [Oxford University Press]
卷期号:60 (11): 5089-5097 被引量:40
标识
DOI:10.1093/rheumatology/keab198
摘要

OBJECTIVE: To evaluate the efficacy and safety of SHR4640, a highly selective urate transporter 1 inhibitor, in Chinese subjects with hyperuricaemia. METHODS: This was a randomized double-blind dose-ranging phase II study. Subjects whose serum uric acid (sUA) levels were ≥480 µmol/l with gout, ≥480 µmol/l without gout but with comorbidities, or ≥540 µmol/l were enrolled. Subjects were randomly assigned (1:1:1:1:1) to receive once daily 2.5 mg, 5 mg, 10 mg of SHR4640, 50 mg of benzbromarone or placebo, respectively. The primary end point was the proportion of subjects who achieved target sUA level of ≤360 µmol/l at week 5. RESULTS: 99.5% of subjects (n = 197) were male and 95.9% of subjects had gout history. The proportions of subjects who achieved target sUA at week 5 were 32.5%, 72.5% and 61.5% in the 5 mg, 10 mg SHR4640 and benzbromarone groups, respectively, significantly higher than the placebo group (0%; P < 0.05 for 5 mg and 10 mg SHR4640 group). The sUA was reduced by 32.7%, 46.8% and 41.8% at week 5 with 5 mg, 10 mg SHR4640 and benzbromarone, respectively, vs placebo (5.9%; P < 0.001 for each comparison). The incidences of gout flares requiring intervention were similar among all groups. Occurrences of treatment-emergent adverse events (TEAEs) were comparable across all groups, and serious TEAEs were not reported. CONCLUSIONS: The present study indicated a superior sUA-lowering effect and well tolerated safety profile after 5-week treatment with once-daily 5 mg/10 mg of SHR4640 as compared with placebo in Chinese subjects with hyperuricaemia. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT03185793.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
牧云萧然发布了新的文献求助10
1秒前
水水的发布了新的文献求助10
1秒前
1秒前
完美世界的应助被跳跳小青蛙采纳,获得10
1秒前
zchhh完成签到 ,获得积分10
2秒前
刻苦夜雪发布了新的文献求助10
2秒前
chen完成签到,获得积分10
2秒前
Wxh发布了新的文献求助30
2秒前
不知发布了新的文献求助10
2秒前
ZM完成签到,获得积分10
2秒前
wg发布了新的文献求助10
3秒前
共享精神的应助被weiwei采纳,获得10
3秒前
3秒前
斯文若血发布了新的文献求助10
3秒前
123456完成签到,获得积分10
3秒前
Hello的应助被zhenghangbin采纳,获得10
4秒前
苦柒发布了新的文献求助10
4秒前
JamesPei的应助被jiabangou采纳,获得10
6秒前
6秒前
6秒前
897102完成签到,获得积分10
6秒前
7秒前
7秒前
bkagyin的应助被huakeguanli采纳,获得10
8秒前
8秒前
CodeCraft的应助被陆羽采纳,获得10
8秒前
可爱的函函的应助被leajay采纳,获得10
9秒前
凶狠的碧完成签到,获得积分20
9秒前
9秒前
七月不远完成签到,获得积分10
9秒前
lin完成签到,获得积分20
10秒前
kk发布了新的文献求助10
10秒前
R_发布了新的文献求助10
11秒前
11秒前
11秒前
11秒前
12秒前
wang发布了新的文献求助10
12秒前
同花顺完成签到,获得积分10
12秒前
厦门大学最伟大的科学家完成签到,获得积分20
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982